Skip to main content

Table 6 Logistic regression model with significant methotrexate and corticoid candidate genes

From: Genomic determinants of long-term cardiometabolic complications in childhood acute lymphoblastic leukemia survivors

 

Extreme phenotype

Dyslipidemia

 

BAD/rs2286615 (C, DOM, ADD)

BAD (CR)

APOB/rs676210 (C, DOM)

BAD/rs2286615 (C, ADD)

BAD (CR)

 

OR (95% CI)

p-value

Age

1.219 (1.005-1.478)

1.213 (1.017-1.447)

1.041 (0.971-1.117)

1.047 (0.961-1.141)

1.037 (0.966-1.114)

0.044

0.032

0.259

0.292

0.313

Gender

1.152 (0.216-6.142)

1.624 (0.340-7.749)

0.726 (0.365-1.444)

1.058 (0.453-2.472)

1.043 (0.506-2.151)

0.869

0.543

0.361

0.896

0.908

Corticoid

1.000 (1.000-1.000)

1.000 (1.000-1.000)

1.000 (1.000-1.000)

1.000 (1.000-1.000)

1.000 (1.000-1.000)

0.577

0.355

0.411

0.519

0.571

Asparaginase

1.000 (1.000-1.000)

1.000 (1.000-1.000)

1.000 (1.000-1.000)

1.000 (1.000-1.000)

1.000 (1.000-1.000)

0.714

0.444

0.372

0.704

0.344

Methotrexate

0.999 (0.999-1.000)

0.999 (0.999-1.000)

1.000 (1.000-1.000)

1.000 (1.000-1.000)

1.000 (1.000-1.000)

0.075

0.048

0.783

0.225

0.642

CRT

14.506 (1.116-188.530)

16.098 (1.220-212.463)

1.572 (0.619-3.994)

2.361 (0.751-7.425)

2.255 (0.843-6.033)

0.041

0.035

0.341

0.142

0.105

Energy balance

0.999 (0.998-1.001)

1.000 (0.998-1.001)

1.000 (0.999-1.000)

1.000 (0.999-1.000)

1.000 (0.999-1.000)

0.297

0.421

0.469

0.319

0.350

Med score

0.652 (0.319-1.329)

0.752 (0.374-1.513)

1.017 (0.813-1.272)

1.029 (0.793-1.334)

0.984 (0.780-1.240)

0.239

0.425

0.885

0.831

0.888

SNP

57.900 (3.152-1063.462)

69.819 (4.202-1159.995)

0.434 (0.215-0.877)

4.022 (1.441-11.226)

3.560 (1.427-8.882)

0.006

0.003

0.020

0.008

0.006

 

Obesity

Pre-hypertension

Insulin resistance

 

BAD/rs2286615 (C, DOM)

BAD/rs2286615

(C, ADD)

CRHR1

(R)

CRHR2

(R)

SERPINA6/rs2228541 (C, ADD)

 

OR (95% CI)

p-value

Age

0.996 (0.914-1.085)

0.998 (0.916-1.087)

1.010 (0.873-1.169)

0.995 (0.869-1.139)

1.085 (0.993-1.185)

0.926

0.959

0.896

0.940

0.073

Gender

1.979 (0.824-4.750)

2.073 (0.854-5.034)

0.081 (0.009-0.741)

0.165 (0.033-0.809)

1.330 (0.562-3.150)

0.127

0.107

0.026

0.026

0.517

Corticoid

1.000 (1.000-1.000)

1.000 (1.000-1.000)

1.000 (1.000-1.000)

1.000 (1.000-1.000)

1.000 (1.000-1.000)

0.998

0.971

0.828

0.830

0.898

Asparaginase

1.000 (1.000-1.000)

1.000 (1.000-1.000)

1.000 (1.000-1.000)

1.000 (1.000-1.000)

1.000 (1.000-1.000)

0.863

0.824

0.621

0.452

0.141

Methotrexate

1.000 (1.000-1.000)

1.000 (1.000-1.000)

1.000 (0.999-1.000)

1.000 (0.999-1.000)

1.000 (1.000-1.000)

0.825

0.786

0.160

0.364

0.935

CRT

1.915 (0.607-6.038)

2.029 (0.636-6.480)

7.685 (0.713-82.885)

3.558 (0.550-23.009)

1.539 (0.463-5.118)

0.267

0.232

0.093

0.183

0.482

Energy balance

1.000 (0.999-1.000)

1.000 (0.999-1.000)

1.000 (0.999-1.001)

0.999 (0.998-1.000)

1.000 (0.999-1.000)

0.137

0.153

0.573

0.168

0.257

Med score

0.921 (0.710-1.195)

0.911 (0.700-1.184)

0.871 (0.562-1.349)

0.806 (0.555-1.170)

0.939 (0.713-1.236)

0.534

0.485

0.536

0.257

0.652

SNP

3.993 (1.410-11.307)

4.044 (1.504-10.879)

76.406 (0.948-6158.616)

3.417 (0.384-30.405)

0.534 (0.286-0.998)

0.009

0.006

0.053

0.271

0.049

  1. Top: Odds ratio (95% CI), bottom: p-value
  2. Boldface: Significant association
  3. C common, CR common/rare, R rare, DOM Dominant effect, ADD Additive effect, CRT Cranial radiotherapy, Med score Mediterranean diet score, Extreme phenotype Three and more cardiometabolic risk factor
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us